Insulinotropic potency of glipizide in vitro A. HerchuelzW. J. Malaisse OriginalPaper Pages: 309 - 310
Pharmacodynamic aspects of two sulphonylurea derivatives glipizide and glibenclamide D. ArtiniR. AbbiatiV. Mandelli OriginalPaper Pages: 311 - 316
Unaltered glucagon secretion after seven days of sulphonylurea administration in normal subjects J. MarcoI. Valverde OriginalPaper Pages: 317 - 319
Pharmacokinetics and pharmacodynamics as well as metabolism following orally and intravenously administered C14-glipizide, a new antidiabetic H. A. E. SchmidtM. SchoogE. Winkler OriginalPaper Pages: 320 - 330
Pharmacokinetics of glipizide in man: Influence of renal insufficiency L. BalantG. ZahndJ. Fabre OriginalPaper Pages: 331 - 338
Glipizide, a new oral antidiabetic agent (report of a controlled clinical study in Sweden) A. JohannessenS. E. Fagerberg OriginalPaper Pages: 339 - 347
Clinical study with glipizide, a new oral antidiabetic drug G. Persson OriginalPaper Pages: 348 - 350
Glipizide versus tolbutamide in maturity-onset diabetes, an open comparative study K. Fuchs OriginalPaper Pages: 351 - 355
Clinical experience with glipizide in the treatment of mostly complicated diabetes A. MasbernardC. GiudicelliJ. Massey OriginalPaper Pages: 356 - 363
An open comparative study of the efficacy and tolerance of a new antidiabetic agent: Glipizide I. De LeeuwH. De BaereH. Verhaegen OriginalPaper Pages: 364 - 366